VitriLife®
Proven thermostabilization platform enabling ambient storage of vaccines and sensitive biologics.
The Cold Chain is Broken
Maintaining temperature-sensitive vaccines and biologics is expensive, inefficient, and often unreliable — especially in long-term storage and global distribution.
Spoilage, delays, and high costs overwhelm health systems and limit access in low-resource settings.
VitriLife® changes that.
Our patented thermostabilization platform eliminates the need for cold storage by transforming sensitive biologicals into shelf-stable formats — without compromising potency or structure.
Why it matters:
-
Reduces cold chain dependency and cost
-
Enables ambient temperature storage and transport
-
Preserves integrity of heat-labile vaccines and fragile biologics
-
Scales globally — from pandemic response to routine immunization
Explore how VitriLife® unlocks global access to temperature-sensitive vaccines and biologics.
Making Biologics Work in the Real World
VitriLife® delivers thermostable solutions for today’s most advanced drug products — eliminating cold chain dependency and unlocking global access.
Vaccines & Immunotherapies
Enable safe, stable delivery of prophylactic and therapeutic vaccines, mRNA constructs, and monoclonal antibodies — without freezing or refrigeration.
Fragile Biologics & Cell-Free Systems
Preserve the potency and integrity of heat-sensitive proteins, peptides, enzymes, and other biologics that are difficult to stabilize with traditional methods like lyophilization.
Global Health & Field Deployment​
Deliver life-saving medications to remote and resource-limited settings with formats that withstand ambient storage and transport, even in extreme climates.
Formulation & Drug Development
Accelerate formulation, clinical testing, and market readiness with a scalable platform that simplifies stability challenges early in the development process.
Our Partners
_svg.png)
and more...
About us
Universal Stabilization Technologies, Inc. ("UST") is a San Diego-based provider of stabilization and delivery enabling technologies with higher yields and at higher storage temperatures than currently possible. UST’s proprietary process enables the thermostabilization of vaccines and biologics during long-term storage, transport, and distribution. UST also develops novel mucosal and transdermal delivery systems for vaccines and biologics.